Haleon plc: 2024 Half Year
Results
1
August 2024: Haleon plc (the
"Company" or "Haleon") (LSE/NYSE: HLN) today announces its half
year results for the year ended 31 December 2024 are available
at: http://www.rns-pdf.londonstockexchange.com/rns/6703Y_1-2024-7-31.pdf
The half year results statement will
also be available on the Haleon website www.haleon.com/investors,
and the results have been submitted in full unedited text to the
Financial Conduct Authority's National Storage Mechanism and will
shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Dividend
Consistent with our previous
guidance to grow the dividend at least in line with earnings, the
Board has declared a H1 2024 interim dividend of 2.0 pence per
ordinary share, up 11% on the interim dividend in 2023. This
interim dividend is expected to be paid on 19 September 2024 to
holders of ordinary shares and US American Depositary Shares
("ADS") on the register as of 16 August 2024 (the record date). The
ex-dividend date is expected to be 15 August 2024 for ordinary
shareholders and 16 August 2024 for holders of ADS. For ordinary
shareholders wishing to participate in the Dividend Reinvestment
Programme ("DRIP"), the election deadline for the DRIP is 30 August
2024.
As previously stated, subject to
market conditions and Board approval, Haleon expects to grow its
ordinary dividend at least in line with adjusted
earnings.
Presentation for analysts and
shareholders
A recorded results presentation by
Brian McNamara, Chief Executive Officer, and Tobias Hestler, Chief
Financial Officer, will be available shortly after 7:00am BST
(8:00am CEST) on 1 August 2024 and can be accessed at
www.haleon.com/investors.
This will be followed by a Q&A session at 9:00am BST (10:00am
CEST).
For analysts and shareholders wishing to ask
questions, please use the dial-in details below which will have a
Q&A facility:
|
UK:
|
+44 (0) 800 358
1035
|
|
US:
|
+1 855 979 6654
|
|
All other:
|
+44 (0) 203 936 2999
|
|
Passcode:
|
646174
|
An archived webcast of the Q&A call will be
available later on the day of the results and can be accessed at
www.haleon.com/investors.
This information contains regulated
information as per 6.3.7R of the Disclosure and Transparency Rules
of the Financial Conduct Authority.
Amanda
Mellor
Company
Secretary
Enquiries
About Haleon
Haleon (LSE/NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.